PUBLISHER: IMARC | PRODUCT CODE: 1451616
PUBLISHER: IMARC | PRODUCT CODE: 1451616
The global contraceptive drugs market size reached US$ 15.8 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 24.5 Billion by 2032, exhibiting a growth rate (CAGR) of 4.9% during 2024-2032.
Contraceptive drugs refer to birth control medications that are used to prevent pregnancy and control the birth rate. They are synthetically formulated using two female hormones, namely estrogen and progestin, which prevent ovulation. These hormones also thicken cervical mucus or alter the womb lining to prohibit the entrance of sperm into the cervix for fertilization and implantation. Contraceptive drugs assist in lowering the risks of acne, bone thinning, ovarian cancer, infections in the fallopian tubes and uterus, and premenstrual syndrome (PMS). As a result, they are administered by healthcare practitioners to inhibit unwanted pregnancy amongst women of childbearing age. At present, they are mainly available in oral, injectable, and topical formulations.
One of the key factors driving the global contraceptive drugs market is the rising consumer consciousness regarding family planning, the increasing population, and the rising instances of unintended pregnancies. In line with this, the shifting inclination of healthcare practitioners toward modern contraceptive methods over conventional procedures, owing to their multiple benefits, including optimal safety, and better clinical outcomes, are acting as another growth-inducing factor. Additionally, the frequent approvals of novel medications by several regulatory bodies, such as the food and drug administration (FDA), are supporting the market growth. Moreover, the advent of gelatin capsules and non-hormonal vaginal gels that create an inhospitable environment for sperm to sustain by maintaining vagina pH levels is impelling the market growth. Apart from this, continuous research and development (R&D) activities and the favorable initiatives undertaken by non-governmental organizations (NGOs) and health agencies to sensitize consumers about contraception techniques, women's health, and sexual wellness are positively augmenting the market growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the global contraceptive drugs market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product, age group and distribution channel.
Oral Contraceptive Pills
Injectable Contraceptives
Topical Contraceptives
15-24 years
25-34 years
35-44 years
Above 44 years
Retail Pharmacy
Hospital Pharmacy
Clinics
Online Channel
Public Channel and NGOs
Others
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being AbbVie Inc., Afaxys Inc., Agile Therapeutics, Amneal Pharmaceuticals Inc., Bayer AG, Johnson & Johnson, Mithra Pharmaceuticals SA, Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd. and Viatris Inc.